Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Front Pharmacol ; 15: 1375993, 2024.
Article in English | MEDLINE | ID: mdl-38659591

ABSTRACT

Cancer stem cells (CSC) are the leading cause of the failure of anti-tumor treatments. These aggressive cancer cells are preserved and sustained by adjacent cells forming a specialized microenvironment, termed niche, among which tumor-associated macrophages (TAMs) are critical players. The cycle of tricarboxylic acids, fatty acid oxidation path, and electron transport chain have been proven to play central roles in the development and maintenance of CSCs and TAMs. By improving their oxidative metabolism, cancer cells are able to extract more energy from nutrients, which allows them to survive in nutritionally defective environments. Because mitochondria are crucial bioenergetic hubs and sites of these metabolic pathways, major hopes are posed for drugs targeting mitochondria. A wide range of medications targeting mitochondria, electron transport chain complexes, or oxidative enzymes are currently investigated in phase 1 and phase 2 clinical trials against hard-to-treat tumors. This review article aims to highlight recent literature on the metabolic adaptations of CSCs and their supporting macrophages. A focus is provided on the resistance and dormancy behaviors that give CSCs a selection advantage and quiescence capacity in particularly hostile microenvironments and the role of TAMs in supporting these attitudes. The article also describes medicaments that have demonstrated a robust ability to disrupt core oxidative metabolism in preclinical cancer studies and are currently being tested in clinical trials.

2.
Biochem Biophys Res Commun ; 386(4): 744-9, 2009 Sep 04.
Article in English | MEDLINE | ID: mdl-19559671

ABSTRACT

Nitric oxide (NO) generated by endothelial NO synthase (eNOS) is a key regulator of endothelial cell (EC) migration. Whereas the effects of acute NO generation are generally stimulatory, the role of chronic basal NO release has not been explored so far. Here, we addressed this question both in HeLa and in human endothelial cells. In stably transfected HeLa cells, inducibly expressing eNOS, expression of the enzyme per se blunted the phosphorylation of Akt/PKB in response to serum and strongly inhibited chemotaxis, an effect partially blocked by eNOS- and soluble guanylyl cyclase (sGC) inhibitors. Likewise, long-term pre-treatment of non-transfected HeLa cells with nanomolar concentrations of an NO donor inhibited subsequent migration, an effect blocked by sGC inhibition and mimicked by a cGMP analog. Finally, EC migration was stimulated by chronic pre-treatment with an eNOS inhibitor. Thus, in addition to its well-known stimulatory role, eNOS attenuates migration through basal long-term NO release.


Subject(s)
Cell Movement , Endothelial Cells/physiology , Nitric Oxide Synthase Type III/metabolism , Nitric Oxide/biosynthesis , Chemotaxis , Endothelial Cells/drug effects , Endothelial Cells/enzymology , Humans , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase Type III/antagonists & inhibitors , Nitric Oxide Synthase Type III/genetics , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism
3.
Exp Cell Res ; 312(6): 877-89, 2006 Apr 01.
Article in English | MEDLINE | ID: mdl-16427620

ABSTRACT

The enzyme endothelial Nitric Oxide Synthase (eNOS) is involved in key physiological and pathological processes, including cell motility and apoptosis. It is widely believed that at the cell surface eNOS is localized in caveolae, where caveolin-1 negatively regulates its activity, however, there are still uncertainties on its intracellular distribution. Here, we applied high resolution confocal microscopy to investigate the surface distribution of eNOS in transfected HeLa cells and in human umbilical vein endothelial cells (HUVEC) endogenously expressing the enzyme. In confluent and non-confluent HUVEC and HeLa cells, we failed to detect substantial colocalization between eNOS and caveolin-1 at the cell surface. Instead, in non-confluent cells, eNOS was concentrated in ruffles and at the leading edge of migrating cells, colocalizing with actin filaments and with the raft marker ganglioside G(M1), and well segregated from caveolin-1, which was restricted to the posterior region of the cells. Treatments that disrupted microfilaments caused loss of eNOS from the cell surface and decreased Ca(2+)-stimulated activity, suggesting a role of the cytoskeleton in the localization and function of the enzyme. Our results provide a morphological correlate for the role of eNOS in cell migration and raise questions on the site of interaction between eNOS and caveolin-1.


Subject(s)
Caveolin 1/metabolism , Cell Movement/physiology , Endothelial Cells/physiology , Nitric Oxide Synthase Type III/physiology , Actins/physiology , Animals , Cattle , Caveolin 1/chemistry , Cell Membrane/chemistry , Cell Membrane/metabolism , Cells, Cultured , Endothelial Cells/cytology , HeLa Cells , Humans , Microscopy, Confocal/methods , Nitric Oxide Synthase Type III/chemistry , Sensitivity and Specificity
4.
Neurotoxicology ; 26(5): 841-5, 2005 Oct.
Article in English | MEDLINE | ID: mdl-15894375

ABSTRACT

The gaseous messenger nitric oxide (NO) plays a bewildering number of roles in fundamental processes, such as cell locomotion, differentiation, proliferation and death. Its different and often contrasting roles may depend on its concentration and intracellular site of generation. We describe here a simple system with which to investigate the roles of NO generated at physiological levels in HeLa cells by eNOS transfected under an inducible promoter. This system has allowed us to uncover unexpected signalling circuits between NO and ceramide, involved in the response of cells to apoptotic stimuli. At present, we are using these cells as a tool to investigate the role of NO in migration.


Subject(s)
Cell Movement/physiology , Nitric Oxide Synthase Type III/physiology , Nitric Oxide/physiology , Apoptosis/physiology , Cell Death/physiology , Cell Survival/physiology , Ceramides/pharmacology , Enzyme Inhibitors/pharmacology , HeLa Cells , Humans , Neovascularization, Pathologic/pathology , Nitric Oxide Synthase Type III/antagonists & inhibitors , Nitric Oxide Synthase Type III/genetics , Signal Transduction/physiology , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...